23 Companies Meet with Novo Nordisk
CLSA, working collaboratively with Novo Nordisk, qualified 23 companies for one-on-one meetings on Dec. 4 at the San Mateo Marriott.
More than 40 bioscience executives met with Novo Nordisk’s business development team to conclude CLSA’s 2012 Pharma Partnering Days. The Novo Nordisk Partnering Day was the fourth successful such event for CLSA this year.
Novo Nordisk has four main areas of interest – Haemophilia, Diabetes and Protein Technologies, Autoimmune Inflammatory Diseases and Protein Delivery Devices.
According to Novo Nordisk, they open to a wide range of partnering models from in-licensing to sophisticated partnerships. Novo Nordisk works with a carefully defined process from opportunity identification to deal making to ensure optimal communication with our potential partners.
The next CLSA Partnering Day will be February 7, 2013. The Leukemia & Lymphoma Society’s (LLS) Therapy Acceleration Program (TAP) is actively seeking to build business alliances with companies that have oncology, inflammation or similar assets with the potential to change the standard of care for blood cancer patients. CLSA has posted more information here.